Trial Profile
A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms STAGGER
- 18 Jun 2020 Status changed from not yet recruiting to recruiting.
- 07 May 2020 Planned initiation date changed from 1 Apr 2020 to 1 Jun 2020.
- 17 Mar 2020 Planned initiation date changed from 15 Feb 2020 to 1 Apr 2020.